From the Department of Paediatric Infectious Diseases and Immunology, University Hospital Southampton, Southampton, United Kingdom.
Julius Global Health, Universitair Medisch Centrum, Utrecht, The Netherlands.
Pediatr Infect Dis J. 2021 Dec 1;40(12):1127-1134. doi: 10.1097/INF.0000000000003261.
The Brighton Collaboration Global Alignment of Immunization Safety in Pregnancy (GAIA) project developed case definitions for the assessment of adverse events in mothers and infants following maternal immunization. This study evaluated the applicability of these definitions to data collected in routine clinical care and research trial records across 7 sites in high-resource settings.
Data collection forms were designed and used to retrospectively abstract the key elements of the GAIA definitions from records for 5 neonatal and 5 maternal outcomes, as well as gestational age. Level of diagnostic certainty was assessed by the data abstractor and an independent clinician, and then verified by Automated Brighton Case logic. The ability to assign a level of diagnostic certainty for each outcome and the positive predictive value (PPV) for their respective ICD-10 codes were evaluated.
Data from 1248 case records were abstracted: 624 neonatal and 622 maternal. Neonatal outcomes were most likely to be assessable and assigned by the level of diagnostic certainty. PPV for preterm birth, low birth weight, small for gestational age and respiratory distress were all above 75%. Maternal outcomes for preeclampsia and fetal growth restriction showed PPV over 80%. However, microcephaly (neonatal outcome) and dysfunctional labor (maternal outcome) were often nonassessable, with low PPVs.
The applicability of GAIA case definitions to retrospectively ascertain and classify maternal and neonatal outcomes was variable among sites in high-resource settings. The implementation of the case definitions is largely dependent on the type and quality of documentation in clinical and research records in both high- and low-resource settings. While designed for use in the prospective evaluation of maternal vaccine safety, the GAIA case definitions would likely need to be specifically adapted for observational studies using alternative sources of data, linking various data sources and allowing flexibility in the ascertainment of the elements and levels of certainty of the case definition.
布莱顿合作组织全球妊娠免疫安全对齐(GAIA)项目为评估母体免疫接种后母婴不良事件制定了病例定义。本研究评估了这些定义在高资源环境下 7 个地点的常规临床护理和研究试验记录中数据的适用性。
设计并使用数据收集表,从记录中回顾性提取 GAIA 定义的 5 个新生儿和 5 个产妇结局以及胎龄的关键要素。数据提取员和独立临床医生评估诊断确定性水平,然后由自动布莱顿病例逻辑验证。评估了为每个结局分配诊断确定性水平的能力以及各自 ICD-10 代码的阳性预测值(PPV)。
从 1248 例病历中提取数据:624 例新生儿和 622 例产妇。新生儿结局最有可能被评估并根据诊断确定性水平进行分配。早产、低出生体重、小于胎龄和呼吸窘迫的 PPV 均高于 75%。子痫前期和胎儿生长受限的产妇结局的 PPV 超过 80%。然而,小头畸形(新生儿结局)和功能失调性分娩(产妇结局)往往无法评估,PPV 较低。
GAIA 病例定义在高资源环境下的各个地点对回顾性确定和分类母婴结局的适用性不同。病例定义的实施在很大程度上取决于临床和研究记录中数据的类型和质量,无论是在高资源还是低资源环境中。虽然这些病例定义旨在用于前瞻性评估母体疫苗安全性,但对于使用替代数据来源的观察性研究,可能需要专门调整 GAIA 病例定义,包括连接各种数据源和灵活确定病例定义的要素和确定性水平。